Biovie Inc. (BIVI): Total Assets
$14.25M
As of 2026-06-30
-26.0%
3-year compound annual growth
+18.7%
5-year compound annual growth
+18.0%
10-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2026-06-30 | $14.25M | -33.9% | 2026-08-13, Balance as of period end |
| 2025-06-30 | $21.56M | -14.5% | 2026-08-13, Balance as of period end |
| 2024-06-30 | $25.21M | -28.2% | 2025-08-15, Balance as of period end |
| 2023-06-30 | $35.10M | +74.5% | 2024-09-30, Balance as of period end |
| 2022-06-30 | $20.11M | +232.7% | 2023-08-16, Balance as of period end |
| 2021-06-30 | $6.05M | +190.2% | 2022-09-27, Balance as of period end |
| 2020-06-30 | $2.08M | -19.1% | 2021-08-30, Balance as of period end |
| 2019-06-30 | $2.57M | +18.3% | 2020-08-07, Balance as of period end |
| 2018-06-30 | $2.18M | -8.0% | 2019-09-27, Balance as of period end |
| 2017-06-30 | $2.36M | -13.1% | 2018-10-05, Balance as of period end |
| 2016-06-30 | $2.72M | +909.0% | 2017-08-24, Balance as of period end |
| 2015-06-30 | $269.5K | -19.0% | 2016-09-28, Balance as of period end |
| 2014-06-30 | $332.9K | -34.2% | 2015-10-01, Balance as of period end |
| 2013-06-30 | $505.7K | n/a | 2014-09-24, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Biovie Inc. (BIVI) | 2026-06-30 | $14.25M | -33.9% |
| Exicure, Inc. (XCUR) | 2025-12-31 | $14.04M | -6.7% |
| Actuate Therapeutics, Inc. (ACTU) | 2025-12-31 | $14.04M | +50.6% |
| CytoDyn Inc. (CYDY) | 2026-05-31 | $13.97M | -22.6% |
| Chemomab Therapeutics Ltd. (CMMB) | 2025-12-31 | $13.81M | -18.6% |
| CalciMedica, Inc. (CALC) | 2025-12-31 | $13.59M | -31.3% |
| Cellectar Biosciences, Inc. (CLRB) | 2025-12-31 | $14.98M | -41.2% |
| Edesa Biotech, Inc. (EDSA) | 2025-09-30 | $13.53M | +254.8% |
| Cingulate Inc. (CING) | 2025-12-31 | $15.07M | +1.4% |
Compare BIVI, XCUR, ACTU, CYDY side by side · Screen every company in Pharmaceutical Preparations ↗